ICH Reflection Paper

International Harmonisation of Real-World Evidence Terminology and Convergence of
General Principles Regarding Planning and Reporting of Studies Using Real-World Data, with
a Focus on Effectiveness of Medicines

Under public consultation until 30 September 2023

Introduction

The role of real-world data (RWD) and real-world evidence (RWE) in supporting the evaluation of medicines across the different stages of their development and lifecycle is evolving [Framework for FDA, United States’ Real-World Evidence Program 2018; Optimizing the Use of Real World Evidence to Inform Regulatory Decision-Making, Health Canada, Canada’s 2019; ENCePP Guide on Methodological Standards in Pharmacoepidemiology, EMA 2022].

In July 2022, the International Coalition of Medicines Regulatory Authorities expressed its strong support to strengthening international collaboration on activities to enable the use of RWE in regulatory decision-making [ICMRA, 2022]. This statement emphasises the engagement of regulatory agencies across the globe to address current gaps due to the lack of standardisation of RWD/RWE terminology and formats, the heterogeneity of data quality across RWD sources, and the various study designs used depending on the types of diseases, medicines, and regulatory context. Addressing these challenges should be supported by common definitions and best practices.

This Reflection Paper outlines a strategic approach for ICH to address some of these challenges. The goal is to further enable the integration of RWE into regulatory submissions and timely regulatory decision-making.

Main technical issues to be addressed

Recognising that traditional randomised clinical trials (RCTs) are foundational for generating evidence on safety and effectiveness pre-authorisation, under appropriate circumstances other approaches can generate evidence suitable for regulatory decision-making. For example, RWE can be generated by using RWD to ascertain endpoints in point-of-care RCTs or serve as a comparator arm in an externally controlled trial (including historically controlled trials)[Framework for FDA, United States’ Real-World Evidence Program (2018)]. RWD are also used in non-interventional studies [FDA Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products (2021)], for example to analyse the utilisation of an authorised medicine in routine medical practice, and to generate evidence that supports regulatory decisions on (long-term) post-marketing safety and effectiveness of medicines [Jonker et al., 2022; Flynn et al., 2022]. RWD can be used to better understand current treatment patterns, co-morbidities, and disease prognosis [Dagenais et al., 2022].

Nevertheless, several challenges exist, including the heterogeneity of RWD types (e.g., electronic health records, registry data, claims data, longitudinal drug prescriptions, dispensing or other drug utilisation data, patient-generated data), healthcare settings (e.g., primary/secondary/tertiary cares, self-treatable conditions), data source characteristics (e.g., purpose, population coverage, data elements, coding terminology), levels of data quality and data validity, and a variety of governance models for data
sharing and access [Bakker et al., 2022; Morton et al., 2016], emphasised by distinct national/regional laws and regulations. The suitability of RWD to generate adequate evidence to support regulatory applications currently requires a case-by-case analysis, which may be driven by different criteria related to the aforementioned factors and depending on the research question(s).

There are currently no internationally harmonised definitions of RWD and RWE.

- The Framework for FDA, United States’ Real-World Evidence Program (2018) defines RWD as “the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources”, and RWE as “clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD. RWE can be generated by different study designs or analyses, including but not limited to, randomised trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective)”.

- RWD has been defined in an EU-led publication as “routinely collected data relating to a patient’s health status or the delivery of health care from a variety of sources other than traditional clinical trials”, and RWE as “the information derived from the analysis of RWD” [Cave et al., 2019].

Although these definitions (and others such as from learned societies, other regulators, etc.) are similar, the terms RWD and RWE are nonetheless used inconsistently and interchangeably [Concato et al., 2020; Concato & Corrigan-Curay, 2022; ENCePP, 2022]. Applying different definitions has limited convergence of best practices among regulators.

Recently published studies have attempted to measure the frequency of use of RWD/RWE in medicine approvals and the extent of use for decision-making [Flynn et al., 2022; Purpura et al., 2021; Eskola et al., 2021]. Variable interpretation of definitions, heterogenous ways of describing and characterising RWD sources, and diverse methodologies used in these studies have led to a different estimated number of medicines’ applications including RWD/RWE. While a significant and increasing proportion of marketing authorisations contain RWE, these observed discrepancies may lead to different levels of acceptance of what is considered to be RWD/RWE across jurisdictions.

Whilst the contribution of what is now called RWD and RWE has long been recognised for safety monitoring and disease epidemiology across medicines’ lifecycles, their use to demonstrate effectiveness is more nascent. Additional work is needed for an in-depth analysis of the actual contribution of RWE to regulatory decision-making, why such information was not considered adequate in some cases, and how it contributed to the approval in other cases. This work would also help complement existing recommendations to medicines developers on the submission of RWE (see the Annex including Regulatory Agencies guidance on RWD/RWE as well as the following publications [Simpson et al., 2022 (part 4); Kent et al., 2021; Griesinger et al., 2022; Simpson et al., 2022 (part 8); Jaksa et al., 2021; Angelis et al., 2018]).

National/regional laws and regulations can present challenges to convergence and harmonisation of terminology and convergence of guidance related to RWD/RWE. However, reaching common understanding at international level on terminology and how RWD/RWE can reduce gaps in knowledge for new and existing medicines, and would help drive forward access to innovative medicines.
Objectives and potential benefits

The objectives of this Reflection Paper are:

- To engage ICH on convergence of terminology for RWD and RWE, on the format for protocols and reports of study results submitted to regulatory agencies throughout the lifecycle of medicinal products, and on promoting registration of protocols and reports;

- To inform the assessment of RWD and RWE for regulatory purposes.

The ultimate benefit of this work is expected to be higher quality RWE that can substantively contribute to the body of evidence supporting the benefit and risk decision-making on medicines.

The following stepwise harmonisation approach is proposed, with the scope and focus to be reassessed prior to initiating the work:

<table>
<thead>
<tr>
<th>Topic</th>
<th>Objective</th>
<th>Deliverables</th>
<th>Tentative timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. RWD/RWE terminology, metadata, and assessment principles</td>
<td>• Promote a common understanding of the types and scope of RWD/RWE</td>
<td>• Common operational definitions of RWD and RWE, with clear scope, breadth of potential RWD sources, and level of granularity (e.g., pertaining to RCTs and non-interventional studies)¹</td>
<td>Submit new ICH topic proposal in Dec 2023 or Dec 2024</td>
</tr>
<tr>
<td></td>
<td>• Guide the discoverability, identification, and description of RWD</td>
<td>• Core list and use of metadata</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Inform the assessment of RWD/RWE for regulatory purposes</td>
<td>• General principles for assessment of RWD/RWE</td>
<td></td>
</tr>
<tr>
<td>2. RWD/RWE protocol &amp; report format, and study transparency</td>
<td>• Agree on common principles regarding formats for RWD/RWE protocols and reports of study results submitted to regulators</td>
<td>• Principles for structure and content of protocols and reports (for medicines developers)</td>
<td>Initiate work after the first guideline reaches Step 4 of the ICH Procedure</td>
</tr>
<tr>
<td></td>
<td>• Promote transparency by encouraging registration of study protocols and study reports in publicly available registries</td>
<td>• Recommended “best practices” for registration of study protocols/results</td>
<td></td>
</tr>
</tbody>
</table>

This Reflection Paper represents the initial step of an incremental approach towards harmonisation of regulatory RWE guidance. The following topics could be considered priorities for subsequent ICH guidelines, based on stakeholders’ feedback:

- Best practices for data quality;

¹ Reference to the ICH M14 glossary will be made during development of the Concept Paper.
• Data standards for RWD;
• Appropriate application of study designs and data analyses.

**Important considerations**

**Stakeholders and consultation**

The complexity of use and impact of RWD/RWE in medicines regulation raise numerous challenges, and the need for involvement of all concerned stakeholders is therefore acknowledged. Should this Reflection Paper be endorsed by ICH, a public consultation is proposed based on the learnings from other ICH guidelines such as ICH E6(R3), ICH E8, and ICH E17 to ensure that all relevant parties are informed and given the opportunity to bring forward their views on technical and operational aspects to be considered when addressing harmonisation of the different focus areas described above. Following the proposed global public consultation on this Reflection Paper and as the guideline work progresses, the Concept Paper and Business Plan should include strategies for extended public consultation and engagement.

**Benefits of ICH harmonisation**

This proposal will aim to benefit all types of medicinal products at any stage of their lifecycle, i.e., from development/pre-approval to post-marketing monitoring. ICH guidance can increase the efficiency of resources across a large number of stakeholders, by aligning expectations of medicines regulators, medicines developers/pharmaceutical industry, patient advocacy groups, contract research organisations, academia, and other stakeholders using RWD to generate evidence on medicinal products.

By supporting the delivery of a regulatory system able to integrate RWE in a more harmonised way into submissions for medicines approval and decision-making, this proposal can support timely decisions on the development of innovative treatments, help to address unmet medical needs and support the safe and effective use of medicines.

**Interface with existing and upcoming guidances (see Annex)**

Several initiatives have been launched in different regions, including but not limited to Europe, the United States and Canada, to evaluate and enable the use of RWE across the spectrum of regulatory use cases that will ultimately lead the development and utilisation of medicines for patients. In December 2018, FDA, United States published a RWE Framework to address current challenges in using RWD and RWE. This was followed by a series of RWD/RWE draft guidances in 2021, a final guidance on submitting documents utilising RWD/RWE in 2022, and a draft guidance on externally controlled trials in 2023. Health Canada is also working towards optimising the use of RWE to inform regulatory decision-making as described in a Health Products and Food Branch Notice, first published in April 2019. In 2020 the HMA/EMA Big Data Task Force issued ten priority recommendations linked to human medicines, related to DARWIN-EU, including the development of the European Medicines Regulatory Network Data Standardisation Strategy to allow convergence with partners on standards and guidelines linked to Big Data and RWE. All these initiatives will support the development of the proposed new ICH guidelines.

Synergies and complementarities are foreseen with other ICH guidelines, for example E6(R3) and its Annex II, ICH M14, as well as ICH M11, currently under development. The ICH guideline M14 on “General principles on planning and designing pharmacoepidemiological studies that utilize real-
ICH Reflection Paper
Endorsed by the ICH Assembly on 13 June 2023

A world data for safety assessment of a medicine” focuses on convergence of guidance and best practices across jurisdictions on planning and designing safety studies that use RWD, whereas the potential for RWE can be broadened to include assessing the effectiveness of medicines and analysing utilisation of marketed medicines administered in routine medical practice. The ICH guideline M11 on “Clinical electronic Structured Harmonised Protocol (CeSHarP)” covers general protocol design principles and approach used to develop the separate associated documents, i.e. the ICH M11 Clinical Electronic Structured Harmonised Protocol Template and the Technical Specification, that are acceptable to all regulatory authorities of the ICH regions. The scope of the M11 guideline focuses on protocol of clinical trials only, whereas RWD have been used mostly in non-interventional studies. The proposed guideline 2 includes the convergence of structure of study reports in addition to study protocols.

Efforts will be needed to ensure that duplications are minimised, and that knowledge gathered from existing projects are leveraged to the maximum so that we can build on lessons learnt. Recognising the need to leverage the relevant expertise (e.g., pharmacoepidemiology, biostatistics, regulatory science) within regulatory authorities and medicines developers to undertake this initiative, and to leave enough time for the maturation of guidances under development, a long-term plan with a stepwise approach is suggested. This strategy will help effectively progress towards harmonisation of terminology related to RWD and RWE and best practices while ensuring complementarity of scope between the new and existing guidelines.

Annex – Regulatory initiatives and guidances related to RWD/RWE

The following table provides examples of existing regulatory initiatives and guidances related to RWD and RWE. It does not constitute a complete inventory of planned or ongoing activities across jurisdictions. In addition, there are many other non-regulatory initiatives and guidances that will be considered as this work progresses (e.g., from learned societies and other relevant projects and stakeholders).

<table>
<thead>
<tr>
<th>Jurisdictions</th>
<th>Regulatory Initiatives and Guidances</th>
<th>Links</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC, Europe (EMA-EC)</td>
<td>Joint HMA/EMA Big Data Initiative, including:</td>
<td>LINK</td>
</tr>
<tr>
<td></td>
<td>• Darwin EU</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Data quality framework for EU medicines regulation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Metadata list describing real-world data sources and studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Good practice guide for the use of the Metadata Catalogue of Real-World Data Sources</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Data standardization strategy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other Guidances:</td>
<td>LINK</td>
</tr>
<tr>
<td></td>
<td>• CHMP guideline on registry-based studies</td>
<td>LINK</td>
</tr>
<tr>
<td></td>
<td>• ENCePP Code of Conduct</td>
<td>LINK</td>
</tr>
<tr>
<td></td>
<td>• ENCePP Guide on Methodological Standards in Pharmacoepidemiology</td>
<td>LINK</td>
</tr>
<tr>
<td></td>
<td>• Good pharmacovigilance practices (GVP) Module VIII of post-authorisation safety studies</td>
<td>LINK</td>
</tr>
<tr>
<td></td>
<td>• Scientific guidance on post-authorisation efficacy studies</td>
<td></td>
</tr>
<tr>
<td>FDA, United States</td>
<td>Framework for FDA, United States’ Real-World Evidence Program (2018)</td>
<td>LINK</td>
</tr>
<tr>
<td>Jurisdictions</td>
<td>Regulatory Initiatives and Guidances</td>
<td>Links</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
</tbody>
</table>
| Health Canada, Canada | Individual Guidances:  
• Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products  
• Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products  
• Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products  
• Data Standards for Drug and Biological Product Submissions Containing Real-World Data  
• Submitting Documents Utilizing Real-World Data and Real-World Evidence to FDA for Drugs and Biologics  
• Use of Electronic Health Records in Clinical Investigations  
• Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices  
• Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products  | LINK    |
| MHRA, UK            | Optimizing the Use of Real World Evidence to Inform Regulatory Decision-Making  
Elements of real world data/evidence quality throughout the prescription drug product life cycle  
DRAFT CADTH Real-World Evidence Reporting Guidance | LINK    |
| SFDA, Saudi Arabia  | Guidance on the use of real-world data in clinical studies to support regulatory decisions  
Guideline on randomised controlled trials using real-world data to support regulatory decisions | LINK    |
| Swissmedic, Switzerland | Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making | LINK    |
| HSA, Singapore      | Digital Health - UNDERSTANDING DIGITAL HEALTH PRODUCTS AND THE REGULATIONS | LINK    |
| NMPA, China         | Guidance for Real-World Data Used to Generate Real-World Evidences  
Guidance on the Use of Real-World Evidence to Support Drug Development and Regulatory Decisions  
Guidance on Communication with Regulatory Agency on Real-World Studies to Support Product Registration  
Guidance on the Design and Protocol Development of Real-World Studies | LINK    |
<p>| DKMA                | Danish Health data and registers | LINK    |</p>
<table>
<thead>
<tr>
<th>Jurisdictions</th>
<th>Regulatory Initiatives and Guidances</th>
<th>Links</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHLW/PMDA, Japan</td>
<td>Working group to deal with regulatory issues related to RWD:&lt;br&gt;• Basic Principles on Utilization of Registry for Applications&lt;br&gt;• Basic principles for utilization of medical information databases in post-marketing pharmacovigilance&lt;br&gt;• Points to consider for Ensuring the Reliability in Utilization of Registry Data for Applications&lt;br&gt;• Guidelines for the Conduct of Pharmacoepidemiological Studies in Drug Safety Assessment with Medical Information Databases</td>
<td>LINK</td>
</tr>
<tr>
<td>MFDS, Republic of Korea</td>
<td>Guideline on the use of Medical Information Database (Real World Data) in pharmacoepidemiologic study</td>
<td>LINK</td>
</tr>
<tr>
<td>Worldwide</td>
<td>ICH guidelines:&lt;br&gt;• ICH M14 “General principles on planning and designing pharmacoepidemiological studies that utilize real-world data for safety assessment of a medicine”&lt;br&gt;• ICH M11 “Clinical electronic Structured Harmonised Protocol (CeSHarP)”&lt;br&gt;• ICH E6(R3) “Good Clinical Practice (GCP)” and Annex II on the use of RWD&lt;br&gt;• ICH E8 “General Considerations for Clinical Studies”&lt;br&gt;• ICH E9 (R1) (addendum on estimands) “Statistical Principles for Clinical Trials”&lt;br&gt;• ICH E10 “Choice of Control Group and Related Issues in Clinical Trials”&lt;br&gt;• ICH E11A “Paediatric Extrapolation”&lt;br&gt;ISPE/ISPOR initiatives (non-exhaustive list):&lt;br&gt;• HARPER (<a href="https://onlinelibrary.wiley.com/doi/10.1002/pds.5507">https://onlinelibrary.wiley.com/doi/10.1002/pds.5507</a>)&lt;br&gt;• EQUATOR (<a href="https://www.equator-network.org/">https://www.equator-network.org/</a>)&lt;br&gt;• ISPE guidelines for good pharmacoepidemiology practices (<a href="https://www.pharmacoepi.org/resources/policies/guidelines-08027/">https://www.pharmacoepi.org/resources/policies/guidelines-08027/</a>)&lt;br&gt;• CIOMS Working Group XIII – Real World Data and Real World Evidence In Regulatory Decision Making</td>
<td>ICH CIOMS</td>
</tr>
</tbody>
</table>

162 Bibliography


European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), 2022. ENCePP Guide on Methodological Standards in Pharmacoepidemiology, Chapter 15.6.3 (link)


European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), 2022. ENCePP Guide on Methodological Standards in Pharmacoepidemiology, Chapter 15.6.3 (link)


International Coalition of Medicines Regulatory Authorities (ICMRA), 2022. ICMRA statement on international collaboration to enable real-world evidence (RWE) for regulatory decision-making (link)


RCT Duplicate publications: https://www.rctduplicate.org/publications.html
